Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer

BACKGROUND AND OBJECTIVES: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-α (PDGFRα). In a randomized phase II study, olaratumab plus doxorubicin met its predefined primary endpoint for progression-free survival and achieved a highly signi...

Full description

Saved in:
Bibliographic Details
Published in:Clin Pharmacokinet
Main Authors: Mo, Gary, Baldwin, John R., Luffer-Atlas, Debra, Ilaria, Robert L., Conti, Ilaria, Heathman, Michael, Cronier, Damien M.
Format: Artigo
Language:Inglês
Published: Springer International Publishing 2017
Subjects:
Original Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814542/
https://ncbi.nlm.nih.gov/pubmed/28620891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0562-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items